Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary Sullivan

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Blood|May 10, 2018
Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromesSandhya R Panch, Michael E Bozik, Thomas Brown, et al.
The Journal of Allergy and Clinical Immunology|March 8, 2016
A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitisPatrick M Brunner, Saakshi Khattri, Sandra Garcet, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 29, 2005
Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)Michelle A Lowes, Francesca Chamian, Maria Veronica Abello, et al.
Experimental Dermatology|June 16, 2016
Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitisSaakshi Khattri, Patrick M Brunner, Sandra Garcet, et al.
Journal of the American Academy of Dermatology|January 22, 2018
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trialEmma Guttman-Yassky, Patrick M Brunner, Avidan U Neumann, et al.
Cell Metabolism|March 7, 2020
Circulating Triglycerides Gate Dopamine-Associated Behaviors through DRD2-Expressing NeuronsChloé Berland, Enrica Montalban, Elodie Perrin, et al.
The Journal of Allergy and Clinical Immunology|August 20, 2018
Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumabPatrick M Brunner, Ana B Pavel, Saakshi Khattri, et al.
The American Journal of Tropical Medicine and Hygiene|August 27, 2024
Efficacy of Intensified Hygiene Measures with or without the Addition of Doxycycline in the Management of Filarial Lymphedema: A Randomized Double-Blind, Placebo-Controlled Clinical Trial in TanzaniaAbdallah Ngenya, Ute Klarmann-Schulz, Winfrida John, et al.
Pediatric Pulmonology|May 15, 2003
Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes RegistryCurt Parnes, Judith Guillermin, Rolf Habersang, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Blood|May 10, 2018
Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromesSandhya R Panch, Michael E Bozik, Thomas Brown, et al.
The Journal of Allergy and Clinical Immunology|March 8, 2016
A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitisPatrick M Brunner, Saakshi Khattri, Sandra Garcet, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 29, 2005
Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)Michelle A Lowes, Francesca Chamian, Maria Veronica Abello, et al.
Experimental Dermatology|June 16, 2016
Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitisSaakshi Khattri, Patrick M Brunner, Sandra Garcet, et al.
Journal of the American Academy of Dermatology|January 22, 2018
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trialEmma Guttman-Yassky, Patrick M Brunner, Avidan U Neumann, et al.
Cell Metabolism|March 7, 2020
Circulating Triglycerides Gate Dopamine-Associated Behaviors through DRD2-Expressing NeuronsChloé Berland, Enrica Montalban, Elodie Perrin, et al.
The Journal of Allergy and Clinical Immunology|August 20, 2018
Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumabPatrick M Brunner, Ana B Pavel, Saakshi Khattri, et al.
The American Journal of Tropical Medicine and Hygiene|August 27, 2024
Efficacy of Intensified Hygiene Measures with or without the Addition of Doxycycline in the Management of Filarial Lymphedema: A Randomized Double-Blind, Placebo-Controlled Clinical Trial in TanzaniaAbdallah Ngenya, Ute Klarmann-Schulz, Winfrida John, et al.
Pediatric Pulmonology|May 15, 2003
Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes RegistryCurt Parnes, Judith Guillermin, Rolf Habersang, et al.
Pageof 8